228 related articles for article (PubMed ID: 31931649)
1. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
2. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.
Polk A; Shahmarvand N; Vistisen K; Vaage-Nilsen M; Larsen FO; Schou M; Nielsen DL
BMJ Open; 2016 Oct; 6(10):e012798. PubMed ID: 27798021
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
[TBL] [Abstract][Full Text] [Related]
4. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
[TBL] [Abstract][Full Text] [Related]
5. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Chakrabarti S; Sara J; Lobo R; Eiring R; Finnes H; Mitchell J; Hartgers M; Okano A; Halfdanarson T; Grothey A
Clin Colorectal Cancer; 2019 Mar; 18(1):52-57. PubMed ID: 30396850
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
[TBL] [Abstract][Full Text] [Related]
7. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
[TBL] [Abstract][Full Text] [Related]
8. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
[TBL] [Abstract][Full Text] [Related]
9. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
[TBL] [Abstract][Full Text] [Related]
10. Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
Jin X; Bai Y; Gao L; Wu S
Cancer Chemother Pharmacol; 2019 Sep; 84(3):599-607. PubMed ID: 31203389
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Karakulak UN; Aladağ E; Maharjan N; Övünç K
Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity and capecitabine: a case report.
Singer M
Clin J Oncol Nurs; 2003; 7(1):72-5. PubMed ID: 12629938
[TBL] [Abstract][Full Text] [Related]
13. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).
Kinos S; Hagman H; Halonen P; Soveri LM; O'Reilly M; Pfeiffer P; Frödin JE; Sorbye H; Heervä E; Liposits G; Kallio R; Ålgars A; Ristamäki R; Salminen T; Bärlund M; Shah CH; McDermott R; Röckert R; Flygare P; Kwakman J; Teske A; Punt C; Glimelius B; Österlund P
Acta Oncol; 2024 May; 63():248-258. PubMed ID: 38698698
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
Saneeymehri SS; Markey KR; Mahipal A
J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
[TBL] [Abstract][Full Text] [Related]
15. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Ransom D; Wilson K; Fournier M; Simes RJ; Gebski V; Yip D; Tebbutt N; Karapetis CS; Ferry D; Gordon S; Price TJ
Ann Oncol; 2014 Jan; 25(1):117-21. PubMed ID: 24299960
[TBL] [Abstract][Full Text] [Related]
16. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2012 Jan; 69(1):57-64. PubMed ID: 21603868
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine induced cardiotoxicity: a case report and review of literature.
Tunio MA; Hashmi A; Shoaib M
Pak J Pharm Sci; 2012 Jan; 25(1):277-81. PubMed ID: 22186341
[TBL] [Abstract][Full Text] [Related]
19. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
20. Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity.
Le Brun-Ly V; Martin J; Venat-Bouvet L; Darodes N; Labourey JL; Genet D; Tubiana-Mathieu N
Oncology; 2009; 76(5):322-5. PubMed ID: 19307737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]